Molecular basis for agonism in the BB3 receptor: an epitope located on the interface of transmembrane-III, -VI, and -VII.

J Pharmacol Exp Ther

Institut National de la Santé et de la Recherche Médicale U894, Centre de Psychiatrie et Neurosciences, Equipe de Neurobiologie et Pharmacologie Moléculaire, 2 Ter Rue d'Alésia, 75014 Paris, France.

Published: April 2010

Epitopes determining the agonist property of two structurally distinct selective ligands for the human bombesin receptor subtype 3 (BB3), [D-Tyr6,(R)-Apa11,Phe13, Nle14]-bombesin(6-14) (Pep-1) and Ac-Phe-Trp-Ala-His(TauBzl)-Nip-Gly-Arg-NH2 (Pep-2), were mapped through systematic mutagenesis of the main ligand-binding pocket of the receptor. The mutational map for the smaller Pep-2 spanned the entire binding pocket of the BB3 receptor. In contrast, the much fewer mutational hits for the larger Pep-1 were confined to the center of the pocket, i.e., the opposing faces of the extracellular segments of transmembrane (TM)-III, TM-VI, and TM-VII. All the residues, which upon mutation affected Pep-1, were also hits for Pep-2 and included those that were most essential for the function of Pep-2: LeuIII:04 (Leu(123)), TyrVI:16 (Tyr(291)), and ArgVII:06 (Arg(316)). The BB3 receptor was found to signal with 12% ligand-independent activity that was strongly influenced both positively and negatively by several mutations in the binding pocket. The substitutions, which decreased the constitutive signaling, included not only the major mutational hits for the peptide agonists but also mutations more superficially located in the receptor. It is concluded that activation of the BB3 receptor is dependent upon an epitope in the main ligand-binding pocket at the interface between TM-III, TM-VI, and TM-VII that corresponds to the site where, for example, activating metal ion sites have been constructed previously in 7TM receptors.

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.109.162131DOI Listing

Publication Analysis

Top Keywords

bb3 receptor
16
main ligand-binding
8
ligand-binding pocket
8
binding pocket
8
mutational hits
8
tm-iii tm-vi
8
tm-vi tm-vii
8
receptor
7
bb3
5
pocket
5

Similar Publications

A Robust α-l-Fucosidase from for Glycoengineering Therapeutic Antibodies.

ACS Chem Biol

July 2024

School of Pharmacy, College of Pharmacy, Taipei Medical University, No. 250 Wuxing Street, Taipei 11031, Taiwan.

Article Synopsis
  • Eliminating core fucose from Fc antibody glycoforms can increase the efficacy of therapeutic antibodies, particularly enhancing ADCC, but traditional fucosidases have limitations in effectiveness.
  • A newly identified α-l-fucosidase (fucA) from a bacterium shows high reactivity to specific fucose linkages while demonstrating robust stability and activity under various conditions.
  • Using fucA in glycoengineering of the antibody adalimumab achieved efficient removal of core fucose, leading to a more effective afucosylated form with improved binding to Fcγ receptor IIIa.
View Article and Find Full Text PDF

Protein tyrosine phosphatase 1B (PTP1B) is a validated therapeutic target for obesity, diabetes, and certain types of cancer. In particular, allosteric inhibitors hold potential for therapeutic use, but an incomplete understanding of conformational dynamics and allostery in this protein has hindered their development. Here, we interrogate solution dynamics and allosteric responses in PTP1B using high-resolution hydrogen-deuterium exchange mass spectrometry (HDX-MS), an emerging and powerful biophysical technique.

View Article and Find Full Text PDF

Discovery of Dimethyl Shikonin Oxime 5a, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Type 2 Diabetes Mellitus.

J Med Chem

June 2023

Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.

Bombesin receptor subtype-3 (BB, BRS-3) is an orphan G protein-coupled receptor. The characterization of novel synthetic ligands for BB is an alternative and attractive strategy to study its diverse physiological functions. Here, we uncovered the intimate pairing of DMAKO-00 and its derivatives with BB.

View Article and Find Full Text PDF

Neuromedin B excites central lateral amygdala neurons and reduces cardiovascular output and fear-potentiated startle.

J Cell Physiol

June 2023

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota, USA.

Neuromedin B (NMB) and gastrin-releasing peptide (GRP) are the two mammalian analogs in the bombesin peptide family that exert a variety of actions including emotional processing, appetitive behaviors, cognition, and tumor growth. The bombesin-like peptides interact with three receptors: the NMB-preferring bombesin 1 (BB1) receptors, the GRP-preferring bombesin 2 (BB2) receptors and the orphan bombesin 3 (BB3) receptors. Whereas, injection of bombesin into the central amygdala reduces satiety and modulates blood pressure, the underlying cellular and molecular mechanisms have not been determined.

View Article and Find Full Text PDF

New emerging polybromobiphenyls in serum of general population and their disruption on thyroid hormone receptor β.

Environ Int

August 2022

Wuxi Center for Disease Control and Prevention, Wuxi 214023, China; Research Base for Environment and Health in Wuxi, Chinese Center for Disease Control and Prevention, Wuxi 214023, China. Electronic address:

After the PBBs pollution incident in Michigan, a large number of studies focused on the exposure of people to 2,2',4,4',5,5'-hexabromobiphenyl (BB-153), but paid less attention to other PBBs congeners in human serum. In this study, three monobromobiphenyls (BB-1, BB-2 and BB-3), five dibromobiphenyls (BB-4, BB-7, BB-9, BB-10 and BB-15), decabromobiphenyl (BB-209) and BB-153 in the serum of the general population in Wuxi from 2012 to 2016 were detected by GC-MS/MS. The most abundant congeners in serum samples were BB-1(median 254 ng·g lw), BB-10 (median 141 ng·g lw) and BB-209 (median 68.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!